Dual Targeting of Mesothelin and CD19 with Chimeric Antigen Receptor-Modified T Cells in Patients with Metastatic Pancreatic Cancer

B cells infiltrate pancreatic ductal adenocarcinoma (PDAC) and in preclinical cancer models, can suppress T cell immunosurveillance in cancer. Here, we conducted a pilot study to assess the safety and feasibility of administering lentiviral-transduced chimeric antigen receptor (CAR)-modified autolog...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Molecular therapy 2020-11, Vol.28 (11), p.2367-2378
Hauptverfasser:	Ko, Andrew H., Jordan, Alexander C., Tooker, Evan, Lacey, Simon F., Chang, Renee B., Li, Yan, Venook, Alan P., Tempero, Margaret, Damon, Lloyd, Fong, Lawrence, O’Hara, Mark H., Levine, Bruce L., Melenhorst, J. Joseph, Plesa, Gabriela, June, Carl H., Beatty, Gregory L.
Format:	Artikel
Sprache:	eng
Schlagworte:	Antigens, CD19 - immunology B cells CD19 chimeric antigen receptor GPI-Linked Proteins - antagonists & inhibitors Humans Immunotherapy, Adoptive - adverse effects Immunotherapy, Adoptive - methods Lymphocyte Depletion - methods Mesothelin Neoplasm Metastasis Neoplasm Staging Original pancreatic cancer Pancreatic Neoplasms - immunology Pancreatic Neoplasms - pathology Pancreatic Neoplasms - therapy Pilot Projects Receptors, Chimeric Antigen - immunology T-Lymphocytes - immunology T-Lymphocytes - metabolism Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!